Givinostat Slows Duchenne Muscular Dystrophy Decline
Givinostat (Duvyzat) slowed physical decline as measured by stair climbing speed for a subset of boys with Duchenne muscular dystrophy (DMD), according to the phase III trial that supported the drug’s recent approval for this indication. While the boys still declined over 72 weeks on the oral drug, their times for a four-stair climb assessment […]
Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
CHICAGO — An “adaptive response” treatment strategy identified a subset of patients with HER2-positive early breast cancer who benefited from a chemotherapy-free treatment plan, according to the phase II PHERGain trial. The strategy is based on evaluating an early response to a dual HER2 blockade with trastuzumab (Herceptin) and pertuzumab (Perjeta) with 18F-FDG PET imaging […]
Drug Resistance in People on PrEP Who Acquire HIV
While a small subset of individuals acquired HIV despite being in a pre-exposure prophylaxis (PrEP) program, many of those people had mutations resistant to antiretroviral drugs, according to a study from the Global Evaluation of Microbicide Sensitivity (GEMS) project. Breakthrough HIV infections occurred in 204 individuals in GEMS, out of more than 104,000 people in […]